Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 5;325(1):69-80.
doi: 10.1001/jama.2020.18936.

Management of Crohn Disease: A Review

Affiliations
Review

Management of Crohn Disease: A Review

Kelly Cushing et al. JAMA. .

Abstract

Importance: Crohn disease, a chronic gastrointestinal inflammatory disease, is increasing in incidence and prevalence in many parts of the world. Uncontrolled inflammation leads to long-term complications, including fibrotic strictures, enteric fistulae, and intestinal neoplasia. Therefore, early and effective control of inflammation is of critical importance.

Observations: The optimal management approach for Crohn disease incorporates patient risk stratification, patient preference, and clinical factors in therapeutic decision-making. First-line therapy generally consists of steroids for rapid palliation of symptoms during initiation of anti-tumor necrosis factor α therapy. Other treatments may include monoclonal antibodies to IL-12/23 or integrin α4β7, immunomodulators, combination therapies, or surgery. Effective control of inflammation reduces the risk of penetrating complications (such as intra-abdominal abscesses and fistulae), although more than half of patients will develop complications that require surgery. Adverse reactions to therapy include antibody formation and infusion reactions, infections, and cancers associated with immune modulators and biologics and toxicity to the bone marrow and the liver. Both Crohn disease and corticosteroid use are associated with osteoporosis. Vaccinations to prevent infections, such as influenza, pneumonia, and herpes zoster, are important components of health maintenance for patients with Crohn disease, although live vaccines are contraindicated for patients receiving immune suppression therapy.

Conclusions and relevance: The treatment of patients with Crohn disease depends on disease severity, patient risk stratification, patient preference, and clinical factors, including age of onset and penetrating complications, and includes treatment with steroids, monoclonal antibody therapies, immunomodulators, and surgery. Physicians should be familiar with the advantages and disadvantages of each therapy to best counsel their patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Higgins reported receiving grant funding from the National Institutes of Health, the Crohn’s and Colitis Foundation, Pfizer, AbbVie, Eli Lilly, Twine Clinical Consulting, Target PharmaSolutions, Shire, Seres, Genentech, Janssen, Takeda, and UCB and consulting for Pfizer, Eli Lilly, Takeda, and Arena Pharmaceuticals. No other disclosures were reported.

Figures

Figure 1.
Figure 1.
Characteristics of Crohn Disease
Figure 2.
Figure 2.. Helical Computed Tomography Imaging of Abdomen and Pelvis
Coronal computed tomography views show slightly increased enhancement in the mucosa of the terminal ileum near the ileocecal valve with areas of slight wall thickening and mural stratification with predominantly intramural fat (yellow arrowheads), as well as feculent luminal contents (pink arrowhead). More proximal loops of ileum are slightly dilated (blue arrowheads). From Cheifetz AS. Management of acute Crohn disease. JAMA. 2013;309(20):2150–2158. doi:10.1001/jama.2013.4466.
Figure 3.
Figure 3.. Establishing the Diagnosis of Crohn Disease
Essential components of a proper workup include a comprehensive history, laboratory evaluation, imaging, endoscopy, and biopsy. These elements can assist the clinician in ruling out alternative diagnoses. ARB indicates angiotensin II receptor blocker; CT, computed tomographic; MR, magnetic resonance; NSAID, nonsteroidal anti-inflammatory drug; PCR, polymerase chain reaction.

Comment in

  • Management of Crohn Disease.
    Bayoumy AB, de Boer NKH, Mulder CJJ. Bayoumy AB, et al. JAMA. 2021 May 4;325(17):1793-1794. doi: 10.1001/jama.2021.2918. JAMA. 2021. PMID: 33944879 No abstract available.

References

    1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390 (10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0 - DOI - PubMed
    1. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149(5):1163–1176.e2. doi:10.1053/j.gastro.2015.08.001 - DOI - PMC - PubMed
    1. Jostins L, Ripke S, Weersma RK, et al.; International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124. doi:10.1038/nature11582 - DOI - PMC - PubMed
    1. Liu JZ, van Sommeren S, Huang H, et al.; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979–986. doi:10.1038/ng.3359 - DOI - PMC - PubMed
    1. Khanna S, Raffals LE. The microbiome in Crohn’s disease: role in pathogenesis and role of microbiome replacement therapies. Gastroenterol Clin North Am. 2017;46(3):481–492. doi:10.1016/j.gtc.2017.05.004 - DOI - PubMed

MeSH terms